Lung cancer is a complex and serious disease, of which lung gland cancer, pulmonary carcinoma and small cell lung cancer are common and vary in many ways.
I. Causes of morbidity: The incidence of lung gland cancer is related to smoking, but it is also high among non-smoking female population groups and may be related to environmental factors (e.g., kitchen smoke, air pollution), genetic factors, etc. Pneumoccal cancer is closely related to smoking, and long-term smoking leads to the development of pneumocular carcinoma as a result of a mucous pneumocular spectroplasm. Small-cell lung cancer is also highly associated with smoking, while its incidence may be associated with genetic factors and some unknown factors.
II. Pathological characteristics: lung gland cancer originates mostly in bronchial mucous glands, with tumour cells in glands or nipples. Pulmonary plaster cancer occurs most often in large bronchial tubes above a bronchial tube, with cancer cells organized in a platinum line, with agularization and intercellular bridges. Small cell lung cancer cells have small sizes, little cytogenesis, nuclei, cell forms are similar to lymphocytes and tumour cells are growing rapidly.
III. Clinical performance: Lung gland cancer may not have significant symptoms at an early stage, and some patients may have shown signs of coughing, glitches, chest pain, etc. Pneumonia cancer is often accompanied by coughs, mostly irritating dry coughs, and can also be characterized by coughing and coding, which can occur relatively early due to the close proximity of the tumor to the large bronchial. Patients with small-cell lung cancer often have symptoms such as cough, short-temperature, chest pain and, due to their rapid growth, may experience all-body symptoms such as loss of weight and inactivity in the short term.
Image expression: On the chest X-ray or CT, lung gland cancer is more manifested in periphery swollen, irregular shape, and the edges may be stabbing, foliage, etc. Pneumoccal cancer is mostly of a central type and can be seen in the swelling of the lung door and can cause pneumonia, for example, by blocking the bronchial tubes. Small-cell lung cancer is also of a central type, with the visual edges of the swelling likely to be smoother and the lymphocytes likely to shift at an early stage.
V. Method of treatment: Lung gland cancer can be treated with a target if it has a suitable target, or with a combination of surgery, chemotherapy, decomposition, etc. Pneumonia cancer is relatively sensitive to treatment and surgery is an important treatment, combining chemotherapy for terminal patients. Small-cell lung cancer is mainly based on chemotherapy and leaching, and surgical treatment is only available to very early patients, as this type of lung cancer is often found to have shifted.
Life period: Overall, life period is affected by a number of factors, including phasing, treatment response, etc. Early pulmonary gland cancer, if performed in a timely manner, has a relatively high survival rate of five years, with a certain increase in the life of a terminal patient with a suitable target drug. Although the rate of survival is five years after early pulmonary plaster surgery, treatment for late pulmonary plaster cancer is relatively limited and may not be as advanced as that for lung gland cancer. Small-cell lung cancer is highly malignant and growing rapidly, and even after active treatment, it tends to be the shortest of the three types, with the median life of extended small-cell lung cancer likely to be only about one year, with active treatment of patients of limited duration and only slightly longer.
The three types of lung cancer are characteristic, and early detection, diagnosis and treatment are key to improving the life and quality of life of patients. At the same time, medical research is constantly exploring new treatments that offer more hope for lung cancer patients.
Lung cancer, small cell lung cancer.
